abstract |
The present application relates to compounds of formula n nwherein R 1 , R 2 , R 3 , R 4 , and n are defined hereinn nor to a pharmaceutically active salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD). |